Vindesine
- Generic Name
- Vindesine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C43H55N5O7
- CAS Number
- 53643-48-4
- Unique Ingredient Identifier
- RSA8KO39WH
- Background
Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).
- Indication
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Blast crisis in myelogenous leukaemia, Malignant Melanoma
- Associated Therapies
- -
Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 81
- Registration Number
- NCT06361329
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05049473
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸ICO-Hospital Duran i Reynals, Bellvitge, Spain
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04899570
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- 🇳🇱
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
🇫🇷Unité d'hématologie pédiatrique CHRU de Lille - Hôpital Jeanne de Flandre, Lille, France
🇧🇪UZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
- Conditions
- Interventions
- Drug: BortezomibDrug: BlinatumomabDrug: CyclophosphamideDrug: CytarabineDrug: DaunorubicinDrug: DexamethasoneDrug: MyocetDrug: DoxorubicinDrug: 6-MercaptopurineDrug: EtoposideDrug: Fludarabine PhosphateDrug: PrednisoloneDrug: IfosfamideDrug: TioguaninDrug: PegaspargaseDrug: MethotrexateDrug: ErwinaseDrug: VincristineDrug: Vindesine
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Martin Schrappe
- Target Recruit Count
- 5000
- Registration Number
- NCT03643276
- Locations
- 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹S.O. Annunziata - A. O. Cosenza, Cosenza, Italy
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 402
- Registration Number
- NCT03018626
- Locations
- 🇨🇳
Ru Feng, Guangzhou, Guangdong, China
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02987244
- Locations
- 🇨🇳
Peking Union medical college hospital, Beijing, Beijing, China
🇨🇳Tianjin medical universty cancer institute & hospital, Tianjin, Tianjin, China
Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
- Conditions
- Interventions
- Drug: RituximabProcedure: Cranial irradiationDrug: NelarabineDrug: IdarubicinDrug: PEG-AsparaginaseDrug: ImatinibDrug: FludarabineDrug: DexamethasoneDrug: CyclophosphamideDrug: VincristineDrug: MethotrexateProcedure: Stem cell transplantationDrug: MercaptopurineDrug: CytarabineDrug: VP16Drug: VindesineDrug: Daunorubicin (DNR)Drug: AdriamycinDrug: Prednisolone
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1000
- Registration Number
- NCT02881086
- Locations
- 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany
Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 316
- Registration Number
- NCT02871869
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Xinjiang Medical University, Ürümqi, Xinjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.